Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04847466
Title Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

stomach cancer

Therapies

ALT-803 + PD-L1.t-haNK cells + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.